News | June 11, 2018

Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock WALTHAM, Mass.–(BUSINESS WIRE)–Jun. 11, 2018– Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key...

News | May 24, 2018

Iterum Therapeutics Announces Pricing of Initial Public Offering DUBLIN and CHICAGO, May 24, 2018 /PRNewswire/ — Iterum Therapeutics plc (NASDAQ:ITRM), a clinical-stage pharmaceutical company developing anti-infectives aimed at combatting the global crisis of...

News | May 5, 2018

NeuroStar® Advanced Therapy Reaches Monumental Milestone of 1.7 Million Treatments in the US Non-drug, non-invasive NeuroStar has become a mainstream option for depression patients, and is now covered by most insurance companies and available in 49 states MALVERN,...

News | May 29, 2018

Deciphera Pharmaceuticals Appoints Stephen B. Ruddy, Ph.D. as Chief Technical Officer Senior Executive with Global Pharmaceutical Development and Manufacturing Experience WALTHAM, Mass.–(BUSINESS WIRE)–May 29, 2018– Deciphera Pharmaceuticals, Inc....

News | April 17, 2018

Preclinical Data Demonstrate That Deciphera Pharmaceuticals’ DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in Gastrointestinal Stromal Tumors (GIST) Compared to Approved and Investigational Agents...

News | March 15, 2018

Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson’s Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018 Evanston, Ill., March 15, 2018 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative...